Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA

Cancer Research

Volumn 61, Issue 21, 2001, Pages 7861-7867

  Velders, Markwin P ^a   McElhiney, Sue ^b   Cassetti, Maria Cristina ^b   Eiben, Gretchen L ^a   Higgins, Terry ^b   Kovacs, Gerald R ^b   Elmishad, Amira G ^a   Kast, W Martin ^a   Smith, Larry R ^b  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPLICON; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS PARTICLE; VIRUS REPLICATION; WART VIRUS;

ANIMALS; CANCER VACCINES; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; FEMALE; GENE THERAPY; GENETIC VECTORS; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEINS, VIRAL; REPLICON; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; VACCINES, SYNTHETIC;

EID: 0035503007     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Viruses in human cancers
2. Monographs on the Evaluation of Carcinogenic Risks to Humans
3. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer
4. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
5. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes
6. The E6 and E7 genes of human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes
7. Continued expression of HPV 16-E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras
8. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA
9. Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein
10. Human papillomavirus type 16 (HPV16) gene expression and DNA replication in cervical neoplasia: Analysis by in situ hybridization
11. Cell-mediated immune response to human papillomavirus infection
12. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
13. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors
14. Cervical cancer vaccines: Emerging concepts and developments
15. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a Phase I-II trial
16. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunetherapy for cervical cancer
17. A Phase I trial of a HPV peptide vaccine for women with high grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive
18. Active immunization against cancer cells: Impediments and advances
19. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumor by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7
20. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV 16 tumor model
21. Treatment of established tumors with a novel vaccine that enhances the major histocompatibility class 11 presentation of tumor antigen
22. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors
23. Defined flanking sequences and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine
24. Alphavirus vectors for gene expression and vaccines
25. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo
26. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates
27. Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: Vector design strategies for improved vaccine efficacy
28. Vaccination with macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles
29. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus
30. Sindbis virus: An efficient, broad host range vector for gene expression in animal cells
31. Building better vaccines: How apoptotic cell death can induce inflammation and activate innate and adaptive immunity
32. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis
33. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: Construction of single and multiple mutants in a full-length eDNA clone
34. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes
35. Kinetics of cytokine expression and regulation of host protection following infection with molecularly cloned Venezuelan equine encephalitis virus
36. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
37. Divergent roles for CD4(+) T cells in the priming and effector/memory phases of adoptive immunotherapy
38. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the PIA gene
39. Cancer therapy using a self-replicating RNA vaccine
40. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors
41. Genetic immunization against cervical carcinoma: Induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7